Stock events for Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics' stock has shown an upward trajectory, with a 77.48% increase over the past six months and a 57.76% increase over the past year. Key events include the proposed acquisition by BioMarin for $14.50 per share, strong financial results with a 23.7% year-over-year revenue increase in 2025, pipeline progress with DMX-200, and a consensus "Buy" rating from analysts with an average price target of $27.25.
Demand Seasonality affecting Amicus Therapeutics, Inc.’s stock price
The provided search results do not contain specific information regarding demand seasonality for Amicus Therapeutics, Inc.'s products and services. Demand for its treatments is driven by patient diagnosis and medical need rather than seasonal fluctuations. Consistent growth in product sales, driven by new patient starts and strong compliance, suggests a steady demand pattern.
Overview of Amicus Therapeutics, Inc.’s business
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. Key products include Galafold for Fabry disease, Pombiliti + Opfolda for late-onset Pompe disease, and DMX-200 for FSGS kidney disease. The company also has a pipeline of gene therapies and combination therapies.
FOLD’s Geographic footprint
Amicus Therapeutics discovers, develops, and delivers medicines in the United States and internationally. Galafold is approved and marketed in the United States, European Union, and other territories. The company maintains research and development operations in multiple locations across the United States and Europe.
FOLD Corporate Image Assessment
Amicus Therapeutics maintains a strong brand reputation within the rare disease community due to its patient-dedicated approach. The successful commercialization of Galafold and Pombiliti + Opfolda, advancements in the clinical pipeline, and the strategic acquisition by BioMarin have positively affected the company's reputation.
Ownership
Amicus Therapeutics has a diverse ownership structure, with institutional investors holding a significant portion of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Perceptive Advisors LLC, which is the largest individual shareholder. Insiders have sold more stock than they have bought in the past three months.
